FORTHCOMING PAPERS IN THE OCTOBER ISSUE OF THE BRITISH JOURNAL OF CANCER

Volume 54, No. 4 October 1986

Main Papers

GROWTH AND RADIOSENSITIVITY OF MALIGNANT MELANOMA MULTI-CELLULAR SPHEROIDS INITIATED DIRECTLY FROM SURGICAL SPECIMENS OF TUMOURS IN MAN. Rofstad, E.K.

COMBINATIONS OF SINGLE DOSES AND FRACTIONATED TREATMENTS OF CIS-DICHLORODIAMMINEPLATINUM (II) AND IRRADIATION: EFFECT ON MOUSE LIP MUCOSA. Landuyt, W., Ang, K.K. & van der Schueren, E.

DRUG SENSITIVITY OF SMALL CELL CARCINOMA OF LUNG BY CLONOGENIC ASSAY IN SEVERAL MEDIA. Simmonds, A.P., Hamilton, P.S., Kerr, H., Harvey, K., Moyes, P., Davidson, K.G. & Fairnhey, A.

PHARMACOKINETICS AND ANTI-TUMOUR ACTIVITY OF LM985 IN MICE BEARING TRANSPLANTABLE ADENOCARCINOMAS OF THE COLON, Double, J.A., Bibby, M.C. & Loadman, P.M.

METABOLIC SUBSTRATE UTILIZATION BY A TUMOUR CELL LINE WHICH INDUCES CACHEXIA IN VIVO. Tisdale, M.J. & Brennan, R.A.


RECOVERY OF CELL SUBPOPULATIONS FROM HUMAN TUMOUR XENOGRAFTS FOLLOWING DISASSOCIATION WITH DIFFERENT ENZYMES. Alatalin-I-Turner, M.J. & Siemann, D.W.

THE EFFECT OF PASSAGE IN VIVO AND IN VITRO ON THE PROPERTIES OF MURINE FIBROSARCOMAS. Woodruff, M.F.A., Hodson, B.A. & Deane, D.L.

THE IMMUNOHISTOCHEMICAL DETECTION OF LYMPH NODE METASTASES FROM INFLTRATING LOBULAR CARCINOMA OF THE BREAST. Bussolati, G., Gugliotta, P., Morra, I., Pietribiasi, F. & Berardengo, E.


ROLE OF AMINOGLUTETHIMIDE IN MALE BREAST CANCER. Harris, A.L., Dowsett, M., Stuart-Harris, R. & Smith, I.E.

THE USE OF EXPERT SURROGATES TO EVALUATE CLINICAL TRIALS IN NON-CELL LUNG CANCER. Mackillop, W.J., Ward, G.K. & O'Sullivan, B.

TIME TRENDS IN PREVALENCE OF CERVICAL CYTOLOGICAL ABNORMALITY IN WOMEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC AND THEIR RELATIONSHIP TO TRENDS IN SEXUAL ACTIVITY AND SPECIFIC INFECTIONS. Armstrong, B.K., Allen, O.V., Brennan, B.A., Fruzynski, I.A., de Klerk, N.H., Waters, E.D., Machin, J. & Gollow, M.M.

BLACK TEA CONSUMPTION AND CANCER RISK: A PROSPECTIVE STUDY. Heilbrun, L.K., Nomura, A. & Stemmermann, G.N.


THE TREATMENT OF ANIMAL TUMOURS AND THEIR METASTASES WITH 4-HYDROXYANISOLE. Kanclerz, A. & Chapman, J.D.

Short Communications

ACCUMULATION OF BASEMENT MEMBRANE COMPONENTS IN INTERFACE BETWEEN GASTRIC CARCINOMA CELLS AND FIBROBLASTS IN VITRO. Sobue, M., Takeuchi, J., Tsukidate, K., Toida, M., Akao, S., Fukatsu, T., Nagasaka, T. & Nakashima, N.

THE EFFECT OF ADJUVANT CYCLOPHOSPHAMIDE OR TAMOXIFEN ON THE NUMBERS OF LYMPHOCYTES BEARING T CELL OR NK CELL MARKERS. Cameron, A.E.P., Reilly, F., Tee, D., Vergani, D., Lowe, D., Baum, M. & Sheard, C.

PHENOTYPIC PROFILE OF HUMAN NEUROBLASTOMA CELL LINES: ASSOCIATION WITH MORPHOLOGICAL CHARACTERISTICS. Komada, Y., Azuma, E., Kamiya, H. & Sakurai, M.
Special Report


Human Cancer


I. YRON, M. SCHICKLER, B. FISCH, H. PINKAS, J. OVADIA and I.P. WITZ: The immune system during the pre-cancer and early cancer period. IL-2 production by PBL from post-menopausal women with and without endometrial carcinoma.


O. CARPEN, O. SAKSELA and E. SAKSELA: Identification and localization of urokinase-type plasminogen activator in human NK-cells.


C. LA VECCIA, P. LIATI, A. DECARLI, I. NEGRELLO and S. FRANCESCHI: Tar yields of cigarettes and the risk of oesophageal cancer.

Experimental Cancer


A. BENOMAR, D. GERLIER and J.-F. DORE: Interactions with host macrophages and ability of human melanoma cell lines to grow in nude mice.

S.R.S. RANGAN, L.N. MARTIN, B.E. BOZELKA, N. WANG and B.J. GORMUS: Epstein-Barr virus-related herpesvirus from a rhesus monkey (Macaca mulatta) with malignant lymphoma.


Notice to Contributors

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr Michael Moore. The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission.

Manuscripts should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors full names, affiliation and addresses; and a summary of not more than 200 words. The author and address to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~1500 words) should not have the above section headings nor a summary.

The Editor reserves the right to make literary corrections.

Titles These are the most read part of papers. Authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters.

References Only papers closely related to the author's work should be quoted, and these should be to original papers only. Exhaustive lists should be avoided.† References in the text should be made by giving the author's surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author's responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors' names should be given in full (except if there are more than 6 authors, when the first 3 names should be followed by "and x others", x being the actual number). Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors' initials), followed by the volume number and the page number, e.g.:


References to books and monographs should appear as in the following examples:


Abbreviations and units should follow the standards laid down in Units Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Figures In the text Arabic numbers should be used and all illustrations should be specifically referred to in the text, e.g. (Figure 2). All illustrations should be submitted at about 1½ times the intended final size and should be numbered as figures whether they are photographs, representational drawings or line diagrams and graphs.

Photographs and photomicrographs should be unmounted glossy prints, should not be retouched, and should be chosen to exclude technical artefacts. Magnification is best indicated by a line representing a defined length included within the photograph. Areas of key interest and/or critical reproduction should be indicated on a flimsy overlay attached to the photograph or on a photocopy. All annotation and lettering should be indicated in the same way, and preferably not included on the original print. Clearly contrasted and focussed prints are essential for adequate reproduction.

Line diagrams and graphs should be on separate sheets; they must be drawn with black Indian ink on white paper, of such originals. Lettering on figures should be minimal and must not duplicate the legend. The use of symbols should be consistent within papers, and explanation of symbols should be included in the caption, not on the figure.

A photocopy of all illustrations should be submitted.

Table These should be as few as possible and should present only essential data. They should be typewritten on separate sheets, have a title or caption, and given Roman numbers.

Proofs Two marked copies of the proofs will be sent to the principal authors which should be read carefully for errors. One corrected copy must be returned to the Editor within 3 days. Major alterations to the text cannot be accepted.

Copyright Assignment The principal author must complete and return to the Publisher the Copyright Assignment Form enclosed with the proofs.

Offprints Twenty-five offprints will be supplied free of charge to the principal author. Additional offprints may be ordered on the form accompanying proofs. The charges are necessarily higher if orders are received after the issue has gone to press.

*Editorial correspondence should be addressed to the Editor, Dr Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

†Citation of Conference Proceeding or Meetings Abstracts should be avoided unless there is no other reference.
EUROPEAN ASSOCIATION FOR CANCER RESEARCH

CALL FOR MEMBERS

The European Association for Cancer Research is a voluntary non-profit making organization with the major aim to advance cancer research by facilitating communication between research workers, including the organization of meetings. Members of the Association receive Newsletters which contain details of EACR Meetings as well as a comprehensive summary of forthcoming meetings on or related to cancer research. These are circulated in the spring and autumn of each year, and a Directory of the membership is prepared and distributed every two years. Members are entitled to reduced registration fees when attending the major biennial meetings of the Association and they are eligible for a special personal subscription rate of $45 per year for the purchase of the European Journal of Cancer and Clinical Oncology, which is the Official Journal for the EACR. The EACR is a founder member society of the Federation of European Cancer Societies which, among its activities, sponsors the biennial European Conference on Clinical Oncology.

The membership of the EACR now exceeds 1,000 cancer researchers and the Association is seeking to increase its representation in individual countries in Europe by inviting researchers to apply for membership. Membership is open to those who possess an academic degree or the equivalent and have held an appointment or worked actively in cancer research for at least two years. The annual membership fee is 25DM.

Please apply to the Secretariat of the EACR at the following address for further details and membership application forms:

Dr. M.R. Price, Secretariat of EACR,
Cancer Research Campaign Laboratories,
University of Nottingham, Nottingham NG7 2RD, U.K.

IXth MEETING OF THE EACR, HELSINKI, FINLAND, 1987

The IXth Meeting of the EACR will be held in Helsinki, Finland from 1st to 3rd June, 1987.

Host Organizations and Committees:

Organizing Committee:
A. VAHERI, Chairman
K. ALITALO, Secretary
K. HEMMINKI
J. SUNI, Treasurer
L. TEPO

Honorary Committee:
E.A. SAXÉN, Honorary President
L.HOLSTI
J. RANTANEN

Cancer Society of Finland:
M. TURUNEN, President
N. VOIPIO, Secretary General

Institute for Occupational Health:
J. RANTANEN, Director

Executive Committee of the EACR:
J. KIELER, President
M.R. CHORAZY, Vice-President
M.R. PRICE, Secretary
L. PREUSSMANN, Treasurer
P.M. COMOGLIO
M.F. RAJEWSKY
M. ROBERFROID
J.-C. SALOMON
V. UJHÁZY

International Scientific Advisors
J.M. BISHOP
G. KLEIN
R.A. WEISS
H. ZUR HAUSEN

Preliminary Scientific Programme:

Plenary lectures on:
Molecular biology of oncogenes
Mutagenesis--carcinogenesis
Environmental carcinogenesis

Seminars and Posters Sessions on:
Cellular oncogenes and transforming proteins
Chromosomes and cancer genetics
Viral carcinogenesis
Growth factors hormones and cancer